Research and Markets: Age-Related Macular Degeneration Pipeline Highlights Report 2014-2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3rjscn/agerelated) has announced the addition of the "Age-Related Macular Degeneration Pipeline Highlights - 2015" report to their offering.

The latest report Age-Related Macular Degeneration Pipeline Highlights - 2015, provides most up-to-date information on key pipeline molecules in the global Age-Related Macular Degeneration market. It covers emerging therapies for Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Age-Related Macular Degeneration pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Age-Related Macular Degeneration pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Age-Related Macular Degeneration pipeline molecules by the Originator Company.

Short-term Launch Highlights:

Find out which Age-Related Macular Degeneration pipeline products will be launched in the US and Ex-US till 2017.

Key Topics Covered:

1. Age-Related Macular Degeneration Pipeline by Stages

2. Age-Related Macular Degeneration Pipeline by Drug Class

3. Age-Related Macular Degeneration Pipeline by Company

4. Age-Related Macular Degeneration Phase 3 Clinical Trial Insights

5. Age-Related Macular Degeneration Phase 2 Clinical Trial Insights

6. Age-Related Macular Degeneration Phase 1 Clinical Trial Insights

7. Age-Related Macular Degeneration Preclinical Research Insights

8. Age-Related Macular Degeneration Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information visit http://www.researchandmarkets.com/research/3rjscn/agerelated

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals